A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

High-risk acute promyelocytic leukemia (APL) remains a therapeutic challenge, with higher associated rates of early mortality and relapse than standard-risk APL. All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) is a well-established treatment for patients with standard-risk APL, but it is...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood Adv
Main Authors: Lancet, Jeffrey E., Moseley, Anna B., Coutre, Steven E., DeAngelo, Daniel J., Othus, Megan, Tallman, Martin S., Litzow, Mark R., Komrokji, Rami S., Erba, Harry P., Appelbaum, Frederick R.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2020
主題:
Myeloid Neoplasia
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189292/
https://ncbi.nlm.nih.gov/pubmed/32330241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001278
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍